Quick Answer
Royalty Pharma plc reported Net Income Loss of $770.95 million for the year ending 2025.
- Royalty Pharma plc showed a decrease of -10.2% in Net Income Loss from 2024 to 2025.
- This data is from Royalty Pharma plc's annual report (Form 10-K), filed with the SEC on February 11, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2019: $151.71 million | Q3 2019: $408.98 million | Q1 2020: $71.24 million | Q2 2020: $442.07 million | Q3 2020: $290.63 million | Q1 2021: $69.12 million | Q2 2021: $440.78 million | Q3 2021: $101.93 million | Q1 2022: $51.76 million | Q2 2022: $304.50 million | Q3 2022: $142.65 million | Q1 2023: $340.76 million | Q2 2023: $227.63 million | Q3 2023: $72.11 million | Q1 2024: $4.78 million | Q2 2024: $102.00 million | Q3 2024: $543.99 million | Q1 2025: $238.35 million | Q2 2025: $30.18 million | Q3 2025: $288.22 million.
- Over the full 8 years of available data (2018 to 2025), Royalty Pharma plc's Net Income Loss has declined by 44.0%.
- Historical annual values: Fiscal year 2025: $770.95 million | Fiscal year 2024: $858.98 million | Fiscal year 2023: $1.13 billion | Fiscal year 2022: $42.83 million | Fiscal year 2021: $619.73 million | Fiscal year 2020: $975.04 million | Fiscal year 2019: $2.35 billion | Fiscal year 2018: $1.38 billion.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: